SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.76 |
| Enterprise Value ($M) | -6.97 |
| Book Value ($M) | 18.44 |
| Book Value / Share | 12.23 |
| Price / Book | 0.15 |
| NCAV ($M) | 15.17 |
| NCAV / Share | 10.07 |
| Price / NCAV | 0.18 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.34 |
| Return on Assets (ROA) | -0.38 |
| Return on Equity (ROE) | -0.46 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.03 |
| Current Ratio | 7.03 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 17.68 |
| Assets | 20.95 |
| Liabilities | 2.51 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Baharaff Allen | 2.60 | -86.10 | |
| 13G/A | CVI Investments, Inc. | 9.90 | -59.68 | |
| 13G/A | Otsuka Masaya | 0.00 | ||
| 13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,404 | 10,113 | 33.66 | |
| 6,404 | 15,453 | 41.44 | |
| 35,167 | 91,911 | 38.26 | |
| 6,194 | 14,335 | 43.21 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GALT – Galectin Therapeutics Inc. | GDTC – CytoMed Therapeutics Limited |
| GELS – Gelteq Limited | GLSI – Greenwich LifeSciences, Inc. |
| GLTO – Galecto, Inc. |
Financial data and stock pages provided by
Fintel.io